A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson’s patients, according to results of a Phase 2 study. The approach introduces a gene into the brain to normalize chemical signaling.
A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson’s patients, according to results of a Phase 2 study. The approach introduces a gene into the brain to normalize chemical signaling.